Programmed cell death is an important process for the maintenance of homeostasis in multicellular organisms (1, 2) . Virtually all cells in such organisms have the capacity to undergo this form of death, and thus the onset of the process must be under tight physiological control. Genetic studies in lower organisms have identified several genes that control the onset and execution of programmed cell death (3, 4) , and additional studies have shown that apoptosis in mammalian cells is controlled by homologous genes that have been conserved throughout evolution (5) . These studies have demonstrated that apoptosis requires the action of the caspases, a set of death effector cysteine proteases with specificity for Asp-x bonds (6, 7) . Another set of proteins, the Bcl-2 family, control the activation of caspases (8 -10) . The antiapoptotic members of the Bcl-2 family, including Bcl-2 and Bcl-x L , are localized to the intracellular membranes of the mitochondria, endoplasmic reticulum, and nuclear envelope (11, 12) . However, many questions remain concerning the molecular mechanism by which these membrane-bound Bcl-2 family members exert their control over caspase activation. Recent reports have demonstrated that the mitochondrial protein cytochrome c can promote caspase activation in a cell-free apoptosis system (13) . Furthermore, it was shown that cytochrome c is released from mitochondria in cells undergoing apoptosis and that this release is prevented by Bcl-2 or Bcl-x L expression (14 -16) . Bcl-2 has also been shown to regulate cytochrome c release from isolated mitochondria (14, 15) . These observations led to the hypothesis that cytochrome c release is an obligate step in the apoptotic pathway and that antiapoptotic Bcl-2 family members function primarily to regulate cytochrome c release (13) (14) (15) (16) . However, to date, no data has been presented concerning a causative apoptotic role for cytochrome c in intact cells. Here, we utilize cellular microinjection techniques to analyze the effects of cytochrome c on the initiation of apoptosis in living cells and to assess the relationship between cytochrome c release and Bcl-x L function.
MATERIALS AND METHODS
Cell Culture and Apoptosis Assay-MCF7 cells (17) stably transfected to express the Fas antigen alone (denoted MCF7F) or both Fas and Bcl-x L (denoted MCF7F/Bcl-x L ) (gifts of Dr. V. Dixit, University of Michigan) were grown in RPMI 1640 containing 10% fetal bovine serum, 200 g/ml G418, and 100 g/ml hygromycin. Human embryonic kidney 293 and HeLa cells (American Type Culture Collection) were cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum, 2 mM glutamine, and 1 ϫ penicillin/streptomycin. Cells were plated on glass cellocate coverslips (Eppendorf) at a density of 40,000/well in 24-well plates for 17-20 h prior to microinjection or cytokine treatment. For experiments utilizing cytokines as death stimuli, cells were treated with either 500 ng/ml anti-Fas (clone CH-11, PanVera Labs, Madison, WI) plus 1 g/ml cycloheximide, 100 ng/ml TNF 1 (R & D Systems) plus 1 g/ml cycloheximide, or cycloheximide * The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
‡ To whom correspondence should be addressed: IDUN Pharmaceuticals, Inc., 11085 N. Torrey Pines Rd., Suite 300, La Jolla, CA 92037. Tel.: 619-623-1330; Fax: 619-625-2677; E-mail: lfritz@idun.com. alone. Following microinjection or cytokine treatment, flat cells (normal) and round/shrunken cells with condensed nuclei (apoptotic) were counted and are presented as percent apoptotic cells. In microinjection experiments, 100 -150 cells were counted for each condition; in experiments using cytokines as the death stimulus without microinjection, at least 300 cells were counted for each condition.
Microinjection-Cell microinjection was performed on the stage of a Nikon Diaphot 300 inverted microscope using an Eppendorf pressure injector (model 5246) and micromanipulator (model 5171). Microinjection needles (about 0.1-m inner diameter) were pulled from glass capillaries using a horizontal electrode puller (Sutter Instrument, model P-97) and loaded using Eppendorf microloaders. MCF7F or MCF7F/Bcl-x L cells were plated on glass cellocate coverslips (Eppendorf) 24 h prior to injection. To identify injected cells, the injectate contained 0.3% dextran-conjugated Texas Red dye (M r 10,000, lysine fixable, Molecular Probes) in H 2 O. Dye alone or dye plus cytochrome c (Sigma; C7752 from horse heart, diluted in H 2 O and freshly prepared for each experiment) were injected into the cytoplasm of cells (pressure, 80 -100 hPa; time, 0.3 s). Cells were switched into fresh medium immediately after injection. The intracellular concentrations of microinjected proteins are estimated to represent a 10 -100-fold dilution of the pipette concentration based on previous calibrations using similar microinjection apparatus and an estimated cellular volume of 4 -5 pl (18) . Thus, we estimate that the amount of cytochrome c injected is proportional to the pipette concentration and that 40 -400 fg are delivered when the pipette concentration is 1 mg/ml. Accordingly, with a pipette concentration of 30 mg/ml (our maximal concentration) we estimate that 1.2-12 pg per cell are delivered. At various times, injected cells were scored for apoptosis as described above. After scoring for apoptosis, Hoechst dye 33342 (Sigma) was added to the medium to a final concentration of 4 g/ml. Cells were incubated at 37°C for 30 min and photographed under ultraviolet illumination. In some experiments, caspase inhibitors Ac-DEVD-aldehyde (Bachem) or zVAD-fmk (8) were diluted with H 2 O, added to the injection solution at a final concentration of 1 mM, and co-injected with cytochrome c. Myoglobin (from horse skeletal muscle), hemoglobin (human and horse), and histone proteins (Type VI-S and VIII-S) were from Sigma.
Cell Transfection-MCF7F cells were plated on glass cellocate coverslips (Eppendorf) at a density of 60,000/coverslip and placed in single wells of a 24-well plate. Twenty-four hours after plating, cells were co-transfected with 0.2 g of pCMV-green lantern protein (Life Technologies, Inc.) and 0.5 g of either empty pcDNA3 (Invitrogen) or pcDNA3 engineered to express pro-caspase 3, mutated pro-caspase 3 (C163G) (in which cysteine 163 was mutated to glycine using the Quick Change site-directed mutagenesis kit (Stratagene) following the manufacturers protocol), pro-caspase 9, or pro-caspase 10, using Lipofectin (Life Technologies, Inc.). For each pro-caspase expression vector, fulllength coding sequence was subcloned by polymerase chain reaction utilizing Pfu polymerase (Stratagene). Each construct was sequenced in its entirety before use. 24 to 48 h after transfection, green fluorescent cells were microinjected with Texas Red dye alone or dye plus cytochrome c, with or without 1 mM caspase inhibitor. At various times, injected cells were scored for apoptosis as described above.
Cell Fractionation-293, HeLa, and MCF7F cells were harvested by centrifugation at 600 ϫ g for 10 min at 4°C. The cell pellets were washed once with ice-cold phosphate-buffered saline and resuspended with 5 volumes of buffer A (20 mM Hepes, pH 7.5, 10 mM KCl, 1.5 mM MgCl 2 , 1 mM sodium EDTA, 1 mM sodium EGTA, 1 mM dithiothreitol, and 0.1 mM phenylmethylsulfonyl fluoride) containing 250 mM sucrose. The cells were homogenized with 75-100 strokes of a Dounce homogenizer, and the homogenates were centrifuged twice at 750 ϫ g for 10 min at 4°C. The supernatants were centrifuged at 10,000 ϫ g for 15 min at 4°C, and the resulting mitochondrial pellets were discarded. The supernatants of the 10,000 ϫ g spin were further centrifuged at 100,000 ϫ g for 1 h at 4°C, and the resulting supernatants (designated S100) were used for caspase activity assays.
Measurement of Cytochrome c Concentration and Caspase Activity-To determine the amount of cytochrome c per cell, various concentrations of horse heart cytochrome c (standards) and total postnuclear cell lysates derived from 500,000 MCF7F, MCF7F/Bcl-x L , or 293 cells were resolved by SDS-polyacrylamide gel electrophoresis in 16% gels (Novex, La Jolla, CA) and transferred to Immobilon polyvinylidene difluoride membrane (Millipore). Membranes were blocked with phosphate-buffered saline/0.1% Tween 20 ϩ 0.4% casein (I-block, Tropix, Bedford, MA) and probed with monoclonal antibody 7H8.2C12 that recognizes denatured cytochrome c (PharMingen). Blots were washed, incubated with goat anti-mouse IgG conjugated to alkaline phosphatase, and developed by incubation with chemiluminescent substrate (Tropix). Cytochrome c concentration in the extracts was estimated by comparison to band intensity of the standards. To evaluate the ability of cytochrome c to activate caspases in cytoplasmic extracts, 10 g of S100 fraction from each cell preparation was incubated with 0.16 M cytochrome c and 1 mM dATP at 30°C for 1 h in a final volume of 10 l of buffer A. At the end of the incubation, the reaction mixture was transferred to a 96-well plate and DEVD-amc was added to a final concentration of 10 M in 190 l of buffer B (25 mM Hepes, 1 mM EDTA, 0.1% CHAPS, 10% sucrose, 3 mM dithiothreitol, pH 7.5). Fluorescent amc production was measured at excitation 360 nm, emission 460 nm using a Cytofluor II fluorescent plate reader (PerSective Biosystems). Experiments were performed in triplicate, and the activity was expressed as change in fluorescence units per hour per 10 g S100.
RESULTS
To determine a physiologically relevant dose of cytochrome c for cellular microinjection, we determined the total amount of cytochrome c per cell in the 293 and MCF7F cell lines, since this amount would represent the upper bound for endogenous releasable cytochrome c in an intact cell. Using a monoclonal antibody that recognizes denatured human and horse cytochrome c, Western blots were performed on extracts prepared from known numbers of cells, and band intensity was compared with measured amounts of horse heart cytochrome c. The results indicated that 293, MCF7F, and MCF7F/Bcl-x L cells each contain comparable amounts of cytochrome c ranging between 40 and 100 fg/cell (data not shown). Under our experimental conditions we estimate that 40 -400 femtoliters of pipette solution is microinjected per cell, and thus with a 3 mg/ml cytochrome c pipette solution, a minimum of 120 fg cytochrome c is delivered. This amount represents more than the total cytochrome c content per cell for 293 and MCF7F cells.
We then analyzed the effects of cytochrome c injection into the human embryonic kidney 293 cell line. Cells were microinjected with solutions of 0.1-3.0 mg/ml of cytochrome c together with Texas Red (to mark injected cells) and analyzed for the onset of apoptosis (Fig. 1, A and B) . We observed a dose-dependent induction of cell death with a threshold at 0.3 mg/ml. The onset of apoptosis was rapid, with half-maximal effects seen between 2 and 3 h postinjection. Significant apoptosis was observed as early as 1 h following the injection of 3 mg/ml cytochrome c (data not shown). The cytochrome c-induced apoptosis of 293 cells was dependent upon caspase activity, since it was inhibited by co-injection of the caspase inhibitors Ac-DEVD-aldehyde (7) or zVAD-fmk (8) (Fig. 1, A and B) . The induction of apoptosis was specific for cytochrome c microinjection since no effect was seen when equivalent amounts of other heme-containing proteins, myoglobin or hemoglobin, were injected (data not shown). It was also possible that the cytochrome c effects were due to its highly basic character. However, microinjection of the basic histone VI-S and VIII-S proteins did not induce apoptosis (data not shown), further indicating that the cytochrome c effect was specific.
Having demonstrated that cytochrome c microinjection was sufficient to induce caspase-dependent apoptosis in 293 cells, we then analyzed the effects of cytochrome c microinjection into two other cell types; the human breast carcinoma cell line MCF7 stably transfected to express Fas on its surface (MCF7F cells) and the human cervical carcinoma cell line HeLa. Surprisingly, MCF7F cells were completely inert to 3 mg/ml cytochrome c microinjection ( Fig. 2A) . HeLa cells showed a response intermediate between that seen with 293 cells and MCF7F cells. We also evaluated the ability of cytochrome c, in the presence of 1 mM dATP (13) , to activate DEVD-amc cleaving activity in cytoplasmic extracts made from 293, MCF7F, and HeLa cells (Fig. 2B) . The ability of cytochrome c plus dATP to activate DEVD-amc cleaving activity in these extracts correlated precisely with the sensitivity of the respective intact cells to microinjected cytochrome c. These data suggested that the cytochrome c-induced death of intact 293 and HeLa cells was due to activation of endogenous caspases that were either absent or inhibited in MCF7F cytoplasm.
To further analyze the basis for the resistance of MCF7F cells to cytochrome c, we microinjected it into MCF7F cells that had been transiently transfected with expression vectors for various pro-caspases. MCF7F cells do express caspases and can undergo caspase-dependent apoptosis (17, 19) but contain little if any caspase 3 (CPP32).
2 Thus, we first determined if expression of pro-caspase 3 in MCF7F cells would render them sensitive to cytochrome c microinjection. The results indicate that whereas MCF7F cells transfected with a control vector remain insensitive to cytochrome c, microinjection of cells transfected with the pro-caspase 3 vector led rapidly to apoptosis (Fig. 3, A  and B) . This death was due to activation of the expressed caspase since death was inhibited by co-injection of Ac-DEVDaldehyde. Furthermore, expression of a catalytically inactive pro-caspase 3, mutated at the active site cysteine, did not render the cells sensitive to cytochrome c. Transfection with pro-caspase 3 alone was not sufficient to induce apoptosis, and cells remained viable unless microinjected with cytochrome c (Fig. 3A) . Interestingly, cytochrome c sensitivity was conferred only by expression of pro-caspase 3 but not by expression of either pro-caspase 10 (Mch-4) (7, 20) or pro-caspase 9 (Mch-6) (20, 21) (Fig. 3A) . Under our conditions, expression of procaspases 9 and 10 did not cause apoptosis in these cells (but see Duan et al., Ref. 22) .
The fact that MCF7F cells were not killed by cytochrome c injection but are capable of undergoing apoptosis in response to other stimuli (17, 23) presented an opportunity to challenge the hypothesis that Bcl-2 family members function primarily to regulate cytochrome c release. First, we confirmed that treatment with cycloheximide plus either TNF or anti-Fas antibody induced a robust level of apoptosis over an 8-h period in MCF7F cells (17, 19) and that this was effectively inhibited by expression of Bcl-x L (Fig. 4) . However, microinjection of cytochrome c, even at levels estimated to be at least 10-fold greater than the total cytochrome c content of the cell (30 mg/ml pipette concentration) failed to induce apoptosis in cycloheximide-treated MCF7F or Bcl-x L -transfected MCF7F cells. Because these cells were insensitive to injected cytochrome c, these results suggested that the Bcl-x L effects were unlikely to be due to cytochrome c sequestration.
It remained possible, however, that anti-Fas or TNF treatment could have caused cellular events that induced cytochrome c sensitivity in MCF7F cells. If so, Bcl-x L could still function by blocking endogenous cytochrome c release in these death paradigms even though untreated MCF7F cells remained cytochrome c resistant. To evaluate this possibility we tested whether cytochrome c microinjection could overcome the inhibition by Bcl-x L of cycloheximide/anti-Fas-induced death. As shown in Fig. 5 , Bcl-x L transfected MCF7F cells were insensitive to cycloheximide plus anti-Fas treatment with or without cytochrome c microinjection. In contrast, cyclohexi- mide plus anti-Fas treatment killed the control MCF7F cells, and this death was enhanced only slightly by microinjection of cytochrome c. The fact that microinjection of cytochrome c could not overcome the Bcl-x L inhibition of apoptosis demonstrates that the Bcl-x L protection observed in this model was not due to blocking cytochrome c release from mitochondria. DISCUSSION We have used microinjection techniques to characterize the effects of cytoplasmic cytochrome c in intact cells. Normally, cytochrome c is localized exclusively in mitochondria but is released into the cytoplasm during apoptosis; we used microinjection to mimic this release. First, we analyzed three cell lines all of which can undergo caspase-dependent apoptosis in response to certain stimuli but that differ dramatically in their response to microinjection of cytochrome c. Whereas microinjection was sufficient to induce rapid cell death in 293 cells, MCF7F cells were inert; HeLa cells showed intermediate sensitivity. The ability of cytochrome c to induce apoptosis in a cell correlated with its ability to induce caspase activity in cytoplasmic extracts derived from that cell type. Furthermore, induction of apoptosis by cytochrome c was reconstituted in the insensitive MCF7F cells by transfection of pro-caspase 3 (CPP32) but not by two other caspases.
At the highest concentrations used, the amount of exogenous cytochrome c microinjected into cells (1.2-12 pg/cell with 30 mg/ml pipette solution) greatly exceeded the estimated total amount of endogenous cytochrome c (40 -100 fg/cell). These estimates were based on Western blots comparing the band intensity of cell extracts to horse cytochrome c standards. Although the extracts were derived from human cells while the standards were derived from horse, this was unlikely to have underestimated the cytochrome c content per cell. The 7H8.2C12 antibody used in the Western blots was raised against pigeon cytochrome c and shown to react with a 12 amino acid peptide that is identical between horse and human (24, 25) . In addition, quantitative assays demonstrated that the antibody bound with equivalent affinity to pigeon and horse cytochrome c, although they differ at three positions in the relevant 12 amino acid peptide (24). Thus we believe that our Western analysis provides an accurate estimate of cytochrome c content in 293 and MCF7 cells. Our values are lower than those derived from mitochondrial counts in primary hepatocytes where cytochrome c content may be 2-4 pg/cell (26) . However, at the highest pipette concentrations used in our experiments, we delivered amounts of cytochrome c comparable to those present even in the mitochondion-rich primary hepatocyte. Thus, we conclude that MCF7F cells do not undergo apoptosis even when injected with supraphysiological amounts of cytochrome c. Note, however, that the cytochrome c microinjected in these experiments was derived from horse muscle. Although we cannot exclude the possibility that microinjection of human cytochrome c might have demonstrated different effects, horse and human cytochrome c molecules are highly homologous, differing in only 6 out of 104 amino acid residues (25) .
Our results support a model in which cytochrome c can promote and accelerate apoptosis in cells expressing procaspase 3, but they cast doubt on the broader hypothesis (13, 15) that cytochrome c release is necessary for apoptosis to occur in general. Apoptosis in thymocytes does not require procaspase 3 activity, as evidenced by a normal response to apoptotic stimuli in thymocytes derived from caspase 3 knockout mice (27) . In addition, most organs with the exception of the brain have a normal histology in caspase 3 knockout mice, suggesting that apoptosis in most cell types is not dependent on caspase 3 (27) . Furthermore, although MCF7F cells lack procaspase 3, 2 they are fully capable of undergoing rapid apoptosis in response to cytokines plus cycloheximide (Figs. 4 and 5) . Although we did not analyze all pro-caspases, our data suggest that cytochrome c has specificity for pro-caspase 3 as compared with pro-caspases 9 and 10 or the endogenous caspases expressed in MCF7F cells (that include pro-caspases 7 (Mch-3) (19) and 8 (Mch-5, FLICE) 2 ). The apparent specificity of cytochrome c for pro-caspase 3 together with the observation that apoptosis can occur independently of this caspase suggests that cytochrome c release is not necessary for the induction of apoptosis. However, we have observed that cytochrome c is, in fact, released from mitochondria in MCF7F cells following antiFas/cycloheximide treatment. 2 Our data favors the interpretation that this mitochondrial release is a consequence of apoptotic events rather than a cause of caspase activation, however, experiments with Xenopus extracts and U937 cells have suggested that cytochrome c release is not blocked by caspase inhibitors (15, 16) . Further experiments in which cytochrome c activity is blocked or inactivated will be necessary to prove whether or not this mitochondrial protein plays a necessary causative role in apoptosis.
Cytochrome c is synthesized in cells from cytoplasmic mRNA molecules and specifically imported into the mitochondrion where it resides in the space between the inner and outer mitochondrial membranes (28) . Bcl-2 and Bcl-x L are localized to intracellular membranes including the outer mitochondrial membrane (11, 12) , and it has been hypothesized that these proteins exert their antiapoptotic effects by preventing cyto- and MCF7F/Bcl-x L cells were treated with 1 g/ml cycloheximide and microinjected with Texas Red dye alone or dye plus 3 or 30 mg/ml cytochrome c, or were treated with 1 g/ml cycloheximide plus either 100 ng/ml TNF or 500 ng/ml antiFas antibody. Injected or cytokine-treated cells were scored at 4, 6, and 8 h after injection or treatment, respectively. Microinjection of cytochrome c had no effect in either cell type at any dose. In contrast, cycloheximide plus anti-Fas or TNF induce apoptosis in MCF7F cells that is inhibitable by Bcl-x L . Each bar represents mean percentage Ϯ range of apoptotic cells in two experiments. 100 -150 cells were evaluated for each condition in each experiment.
chrome c from being released into the cytoplasm (14 -16) . In support of this view, Bcl-2 expression does inhibit cytochrome c release from mitochondria in cells and from isolated organelles (14 -16) . However, from these experiments it is difficult to distinguish between a direct effect of Bcl-2 on cytochrome c release and an indirect effect whereby Bcl-2 inhibits other proapoptotic events thus preventing mitochondrial damage. Furthermore, the adenovirus-derived Bcl-2 homologue E1B-19K is a potent inhibitor of apoptosis but is largely excluded from the mitochondrial membrane (29, 30) , suggesting the importance of mechanisms that are not specific to mitochondria. Similarly, engineered Bcl-2 molecules targeted to non-mitochondrial intracellular membranes retained activity in certain models of apoptosis (31) . In our experiments, we used the cytochrome c-insensitive MCF7F cell line to study the relationship between the activity of Bcl-x L and cytochrome c release. The fact that MCF7F cells were not sensitive to cytochrome c microinjection allowed us to separate Bcl-x L activity from cytochrome c activity. We reasoned that if Bcl-x L only served to inhibit cytochrome c release, then it was unlikely that Bcl-x L would demonstrate activity in a cytochrome c-resistant cell. However, our data clearly showed that Bcl-x L inhibits apoptosis induced by cycloheximide/cytokine treatment in these cells. Furthermore, if Bcl-x L only inhibited cytochrome c release, then cytochrome c microinjection would specifically overcome the Bcl-x L protective effect and induce apoptosis in MCF7F/ Bcl-x L cells treated with cycloheximide/anti-Fas. However, even under these conditions, microinjection of cytochrome c did not induce death in these cells. We conclude, therefore, that the antiapoptotic activity of Bcl-x L cannot be explained solely by inhibition of cytochrome c release. Although our data cannot exclude the possibility that Bcl-x L also has direct effects on cytochrome c release, this cannot be the only mechanism by which it inhibits apoptosis.
If sequestration of cytochrome c is inadequate to explain the antiapoptotic effects of Bcl-x L , what other mechanisms may be relevant? One likely mechanism involves Bcl-x L interactions with a functional homologue of the Caenorhabditis elegans CED-4 protein (32) . In C. elegans, the ced-4 gene is required for caspase-dependent cell death and may be a target for the inhibitory effects of the bcl-2 homologue, ced-9 (33) (34) (35) (36) . Recent data indicate that the mammalian Bcl-x L and Bcl-2 molecules can bind directly to CED-4 (35-37). Future work will be necessary to identify mammalian CED-4 homologues and to clarify whether or not they are the primary targets of Bcl-2 family proteins. FIG. 5 . Cytochrome c fails to overcome the inhibition of apoptosis by Bcl-x L in MCF7F cells. MCF7F and MCF7F/Bcl-x L cells were treated with 500 ng/ml anti-Fas in the presence of 1 g/ml cycloheximide and microinjected with Texas Red dye alone or dye plus 3 mg/ml cytochrome c or were left uninjected. Cells were scored at 4, 6, and 8 h after injection and treatment. Each bar represents mean percentage Ϯ range of apoptotic cells in two experiments. 100 -150 cells were evaluated for each condition in each experiment.
